IPO Corner: Fabtech Technologies Ltd.

Fabtech Technologies has fixed the price band of ₹ 181/- to ₹ 191 /- per Equity Share of face value ₹ 10/- each for its maiden initial public offer. The Initial Public Offering of the Company will open on Monday, September 29, 2025, for subscription and close on Wednesday, October 1, 2025. Investors can bid for a minimum of Equity Shares and in multiples of Equity Shares thereafter.

• Issue Opens: September 29, 2025
• Issue Closes: October 1, 2025
• Face Value: Rs 10 each
• Price Band: Rs 181 – 191 per share
• Lot Size: 75 Shares
• Listing: BSE NSE

Equity shares outstanding as on date 3, 23, 92, 239 Equity Shares of Rs 10 each. The IPO is a fresh issue for 1,20,60,000 equity shares. The proceeds from the fresh issue to the extent of Rs 127 crore will be for funding the working capital requirements of the company, Rs 30 crore for funding inorganic growth opportunities through acquisitions and general corporate purposes.

The company is a global company headquartered in India, specializing in turnkey engineering solutions for pharmaceuticals, biotech and healthcare companies. Its footprint spans more than 62 countries Middle East, Africa, Asia, Europe, Latin America, North America, etc. The company has presence across some of the key emerging economies like Bangladesh, Egypt, Ethiopia, India, Kenya, Kingdom of Saudi Arabia, Morocco, Nicaragua, Nigeria, South Africa, Turkey, UAE, USA and Tanzania.

The company provides extensive technical expertise and infrastructure to deliver comprehensive solutions for establishing aseptic manufacturing facilities, encompassing everything from design to certification.

The company offers comprehensive start to finish services in greenfield projects, encompassing disease identification, planning, designing, engineering, procurement, quality assurance, logistics management and installation and commissioning for a wide range of customers across various geographies, particularly key emerging economies. Additionally, the company also offers some of its engineering solutions, which majorly include, equipment procurement and supply and logistics management, on a standalone basis, either as part of greenfield or brownfield projects. In such projects, the feasibility study, design and engineering and other execution functions are undertaken by third party solution providers, and our scope is limited to equipment supply or any other services, required by our customers.

The company is a part of Fabtech Group which was established in 1995 and has over 29 years of operating history in executing pharmaceutical turnkey projects. The company has completed 51 projects across Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka and UAE, as on date of filing RHP.  And as on July 31, 2025, the company has an order book aggregating to ₹ 904.4. The company’s revenue from operations was Rs 326.66 crore during FY25 vis-à-vis Rs 193.79 crore during FY23. Its net profit was Rs 46.45 crore during FY25 vis-à-vis Rs 21.73 crore during FY23.